40P - Prognostic role of neutrophil lymphocyte ratio in breast cancer: A single center study

Date 20 November 2015
Event ESMO Symposium on Immuno-Oncology 2015
Session Welcome reception and general Poster viewing
Topics Breast Cancer
Cancer Immunology and Immunotherapy
Presenter Pooja Khullar
Citation Annals of Oncology (2015) 26 (suppl_8): 5-14. 10.1093/annonc/mdv514
Authors P. Khullar
  • Rt, Batra Hospital Medical Research Centre, 110039 - New Delhi/IN

Abstract

Aim

The aim of this study was to determine diagnostic and prognostic roles of the neutrophil to lymphocyte ratio (NLR) in breast cancer patients, in view of disease-specific survival and the intrinsic subtype.

Methods

We carried out a retrospective study of a sequence of 300 breast cancer registered between 2008 and 2012 at R.G.C.I, New Delhi, India.

Results

The median age was 48years (range 18-88). The TNM stage distribution was stage I - 3 %, stage II - 20%, stage III - 57%, and stage IV - 20%. ER/PR and her2neu positivity was 50% and 20%, respectively. Triple-negative breast cancer (TNBC) constituted 30%. Patients with higher NLR (NLR ≥ 2.5) showed significantly lower disease-specific survival rate than those with lower NLR (NLR < 2.5). Higher NLR along with her2neu positive receptor status and positive nodal status were independently correlated with poor prognosis, with hazard ratio 2.08 (95% confidence interval [CI], 1.62-4 .28), 1.93 (95% CI, 1.08-3.99, and 3.23 (95% CI, 1.34-5.83), respectively. Triple-negative subtype was the only intrinsic subtype in which higher NLR patients showed significantly poor prognosis (87.7% vs. 96.7%, p = 0.009).

Conclusions

Patients with an elevated pretreatment NLR showed poorer disease-specific survival than patients without elevated NLR, most evident in the triple-negative subtype. It has been suggested some immune check points are also play a part in the biology of triple-negative breast cancer.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.